CYTK · Cytokinetics Inc · Insider Trading

$65.60 -0.02 (-0.03%) At close · Oct 2

S&P 400 member Russell 2000 member Rebalance outlook locked

Market Cap

$9.20B

139.02M

Volume · Oct 2 2.65M Avg daily vol (3M) 1.93M

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-09-28	Blum Robert I	Director, President & CEO	Convert↑	Common Stock	7,500	$10.60	$79,500	286,044
2026-09-28	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	7,500	$65.46	$490,950	278,544
2026-09-28	Blum Robert I	Director, President & CEO	Convert↓	Non-Qualified Stock Option (Right to Buy)	7,500	—	—	149,245
2026-09-22	Malik Fady Ibraham	Director	Convert↑	Common Stock	3,500	$7.80	$27,300	157,402
2026-09-22	Malik Fady Ibraham	Director	Sell↓	Common Stock	3,500	$68.29	$239,015	153,902
2026-09-22	Malik Fady Ibraham	Director	Convert↓	Non-Qualified Stock Option (Right to Buy)	3,500	—	—	23,386
2026-09-15	Landry Robert E	Director	Sell↓	Common Stock	1,000	$72.13	$72,130	8,184
2026-09-15	Blum Robert I	Director, President & CEO	Sell↓ Filing footnotes — Common Stock (Indirect) Sale of shares of common stock by The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares sold or the proceeds thereof.	Common Stock (I)	97,926	$69.33	$6,789,210	0
2026-09-14	Blum Robert I	Director, President & CEO	Gift↑ Filing footnotes — Common Stock (Indirect) Acquisition of shares by The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares held by the aforementioned trust.	Common Stock (I)	97,926	—	—	97,926
2026-09-14	Blum Robert I	Director, President & CEO	Convert↑ Filing footnotes — Common Stock (Direct) Acquisition of shares of common stock upon exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).	Common Stock	7,500	$10.60	$79,500	385,320
2026-09-14	Blum Robert I	Director, President & CEO	Gift↓ Filing footnotes — Common Stock (Direct) Transfer of shares of common stock to The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares held by the aforementioned trust upon completion of the gift transfer.	Common Stock	97,926	—	—	278,544
2026-09-14	Blum Robert I	Director, President & CEO	Sell↓ Filing footnotes — Common Stock (Direct) Sale of shares of common stock acquired upon exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).	Common Stock	7,500	$73.44	$550,800	377,820
2026-09-14	Blum Robert I	Director, President & CEO	Gift↓ Filing footnotes — Common Stock (Direct) Charitable gift.	Common Stock	1,350	—	—	376,470
2026-09-14	Blum Robert I	Director, President & CEO	Convert↓ Filing footnotes — Non-Qualified Stock Option (Right to Buy) (Direct) Exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).	Non-Qualified Stock Option (Right to Buy)	7,500	—	—	156,745
2026-09-11	Landry Robert E	Director	Sell↓	Common Stock	1,000	$74.66	$74,660	9,184
2026-09-08	Malik Fady Ibraham	Director	Convert↓	Non-Qualified Stock Option (Right to Buy)	3,500	—	—	26,886
2026-09-08	Malik Fady Ibraham	Director	Convert↑	Common Stock	3,500	$7.80	$27,300	157,402
2026-09-08	Malik Fady Ibraham	Director	Sell↓	Common Stock	3,500	$75.46	$264,110	153,902
2026-09-01	PARSHALL B LYNNE	Director	Sell↓	Common Stock	5,000	$71.48	$357,400	10,784
2026-08-31	Callos Andrew	EVP, Chief Commercial Officer	Convert↑	Common Stock	10,000	$23.26	$232,600	68,555
2026-08-31	Blum Robert I	Director, President & CEO	Convert↑	Common Stock	7,500	$10.60	$79,500	385,320
2026-08-31	Callos Andrew	EVP, Chief Commercial Officer	Sell↓	Common Stock	10,000	$70.24	$702,400	58,555
2026-08-31	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	7,500	$70.24	$526,800	377,820
2026-08-31	Blum Robert I	Director, President & CEO	Convert↓	Non-Qualified Stock Option (Right to Buy)	7,500	—	—	164,245
2026-08-31	Callos Andrew	EVP, Chief Commercial Officer	Convert↓ Filing footnotes — Non-Qualified Stock Option (Right to Buy) (Direct) Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.	Non-Qualified Stock Option (Right to Buy)	10,000	—	—	0
2026-08-18	Malik Fady Ibraham	Director	Convert↑	Common Stock	3,500	$7.80	$27,300	157,402
2026-08-18	Malik Fady Ibraham	Director	Convert↓	Non-Qualified Stock Option (Right to Buy)	3,500	—	—	30,386
2026-08-18	Malik Fady Ibraham	Director	Sell↓	Common Stock	3,500	$75.82	$265,370	153,902
2026-08-10	Blum Robert I	Director, President & CEO	Convert↑	Common Stock	7,500	$10.60	$79,500	385,320
2026-08-10	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	7,500	$76.76	$575,700	377,820
2026-08-10	Blum Robert I	Director, President & CEO	Convert↓	Non-Qualified Stock Option (Right to Buy)	7,500	—	—	171,745
2026-07-30	Callos Andrew	EVP, Chief Commercial Officer	Convert↓ Filing footnotes — Non-Qualified Stock Option (Right to Buy) (Direct) Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.	Non-Qualified Stock Option (Right to Buy)	14,000	—	—	10,000
2026-07-30	Callos Andrew	EVP, Chief Commercial Officer	Sell↓	Common Stock	14,000	$79.88	$1,118,320	58,555
2026-07-30	Callos Andrew	EVP, Chief Commercial Officer	Convert↑	Common Stock	14,000	$23.26	$325,640	72,555
2026-07-27	Blum Robert I	Director, President & CEO	Convert↓	Non-Qualified Stock Option (Right to Buy)	7,500	—	—	179,245
2026-07-27	Blum Robert I	Director, President & CEO	Convert↑	Common Stock	7,500	$10.60	$79,500	385,320
2026-07-27	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	7,500	$80.87	$606,525	377,820
2026-07-21	Malik Fady Ibraham	Director	Convert↑	Common Stock	3,500	$7.80	$27,300	157,402
2026-07-21	Malik Fady Ibraham	Director	Sell↓	Common Stock	3,500	$80.59	$282,065	153,902
2026-07-21	Malik Fady Ibraham	Director	Convert↓	Non-Qualified Stock Option (Right to Buy)	3,500	—	—	33,886
2026-07-15	Harrington Robert Arthur	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	151	$82.62	$12,476	21,932
2026-07-15	WIERENGA WENDELL	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	75	$82.62	$6,197	35,563
2026-07-15	Kaye Edward M. MD	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	151	$82.62	$12,476	10,434
2026-07-15	Wysenski Nancy	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	75	$82.62	$6,197	33,992
2026-07-15	Daly James M	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	151	$82.62	$12,476	3,390
2026-07-15	HENDERSON JOHN T	Director	Award↑ Filing footnotes — Common Stock (Direct) Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.	Common Stock	272	$82.62	$22,473	78,360
2026-07-13	Blum Robert I	Director, President & CEO	Convert↑	Common Stock	7,490	$10.60	$79,394	385,310
2026-07-13	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	7,490	$82.02	$614,330	377,820
2026-07-13	Blum Robert I	Director, President & CEO	Sell↓	Common Stock	10	$82.02	$820	377,820
2026-07-13	Blum Robert I	Director, President & CEO	Convert↓	Non-Qualified Stock Option (Right to Buy)	7,490	—	—	186,745

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–50 of 1,704 transactions

Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 11 filings 10 filers Visit website Investor relations